Anesthetic and Analgesic Drug Products Advisory Committee; Cancellation, 42088 [2013-16823]
Download as PDF
<![CDATA[
tkelley on DSK3SPTVN1PROD with NOTICES
42088
Federal Register / Vol. 78, No. 135 / Monday, July 15, 2013 / Notices
health care professionals and other
stakeholders about the public health
risks posed by counterfeit and
unapproved drugs, in addition to safe
purchasing practices, and how FDA can
evaluate that communication and its
impact.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before August 8, 2013. Oral
presentations from the public will be
scheduled between approximately 1
p.m. and 2 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before July 31,
2013. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by August 1, 2013.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Luis G. Bravo
at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
VerDate Mar<15>2010
18:53 Jul 12, 2013
Jkt 229001
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: July 9, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
AGENCY:
[FR Doc. 2013–16831 Filed 7–12–13; 8:45 am]
SUMMARY:
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0001]
Anesthetic and Analgesic Drug
Products Advisory Committee;
Cancellation
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The meeting of the Anesthetic
and Analgesic Drug Products Advisory
Committee scheduled for July 17, 2013,
is cancelled. This meeting was
announced in the Federal Register of
May 17, 2013 (78 FR 29142 to 29143).
This meeting has been canceled due to
new information submitted to the
application. The Agency intends to
continue evaluating the application and,
as needed, will announce future
meeting dates in the Federal Register.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Caleb Briggs, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 31, Rm. 2417, Silver Spring,
MD 20993–0002, 301–796–9001, FAX:
301–847–8533, email:
AADPAC@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), and follow the
prompts to the desired center or product
area. Please call the Information Line for
up-to-date information on this meeting.
Dated: July 9, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–16823 Filed 7–12–13; 8:45 am]
BILLING CODE 4160–01–P
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
Health Resources and Services
Administration
Agency Information Collection
Activities: Proposed Collection: Public
Comment Request
Health Resources and Services
Administration, HHS.
ACTION: Notice.
In compliance with the
requirement for opportunity for public
comment on proposed data collection
projects (Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995), the
Health Resources and Services
Administration (HRSA) announces
plans to submit an Information
Collection Request (ICR), described
below, to the Office of Management and
Budget (OMB). Prior to submitting the
ICR to OMB, HRSA seeks comments
from the public regarding the burden
estimate, below, or any other aspect of
the ICR.
DATES: Comments on this Information
Collection Request must be received
within 60 days of this notice.
ADDRESSES: Submit your comments to
paperwork@hrsa.gov or mail the HRSA
Information Collection Clearance
Officer, Room 10–29, Parklawn
Building, 5600 Fishers Lane, Rockville,
MD 20857.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and draft
instruments, email paperwork@hrsa.gov
or call the HRSA Information Collection
Clearance Officer at (301) 443–1984.
SUPPLEMENTARY INFORMATION: When
submitting comments or requesting
information, please include the
information request collection title for
reference.
Information Collection Request Title:
National Hospital Organ Donation
Campaign’s Activity Scorecard. OMB
No. 0915-xxxx—New.
Need and Proposed Use of the
Information: HRSA’s Healthcare
Systems Bureau, Division of
Transplantation administers the
Workplace Partnership for Life program
under the authority of Section 377A(a)
of the Public Health Service (PHS) Act,
(42 U.S.C. 274f-1). The Workplace
Partnership for Life program seeks to
increase the number of registered organ,
eye, and tissue donors and to increase
awareness about organ donation. HRSA
launched a challenge to hospitals
nationwide to assist in this effort by
conducting donor education and donor
E:\FR\FM\15JYN1.SGM
15JYN1
]]>Agencies
[Federal Register Volume 78, Number 135 (Monday, July 15, 2013)]
[Notices]
[Page 42088]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-16823]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-0001]
Anesthetic and Analgesic Drug Products Advisory Committee;
Cancellation
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The meeting of the Anesthetic and Analgesic Drug Products
Advisory Committee scheduled for July 17, 2013, is cancelled. This
meeting was announced in the Federal Register of May 17, 2013 (78 FR
29142 to 29143). This meeting has been canceled due to new information
submitted to the application. The Agency intends to continue evaluating
the application and, as needed, will announce future meeting dates in
the Federal Register.
FOR FURTHER INFORMATION CONTACT: Caleb Briggs, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, FAX: 301-847-8533, email: AADPAC@fda.hhs.gov, or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington, DC area), and follow the prompts to the desired center or
product area. Please call the Information Line for up-to-date
information on this meeting.
Dated: July 9, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-16823 Filed 7-12-13; 8:45 am]
BILLING CODE 4160-01-P
